Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses

Details Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses

2011-08-09

2011-08-09

Fetterolf, Brandon J (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C560S027000, C549S059000, C514S535000

Reexamination Certificate

active

07994211

ABSTRACT:
Compounds of formula (I) have muscarinic M3 receptor modulating activity; Formula (I) wherein A is an oxygen atom or group —N(R12)—; (i) R1is C1-C6-alkyl or a hydrogen atom; and R2is a hydrogen atom or a group —R5, —Z—Y—R5—Z—NR9R10; —Z—CO—NR9R10; —Z—NR9—CO—R5; or —Z—CO2H; and R3is a lone pair, or C1-C6-alkyl in which case the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; or (ii) R1and R3together with the nitrogen to which they are attached form a heterocycloalkyl ring, and R2is a hydrogen atom; or a group —R5, —Z—Y—R5, —Z—NR9R10, —Z—CO—NR9R10, —Z—NR9—CO—R5, or —Z—CO2H, in which cases the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; or (iii) R1and R2together with the nitrogen to which they are attached form a heterocycloalkyl ring, said ring being substituted by a group —Y—R5, —Z—Y—R5, —Z—NR9R10; —Z—CO—NR9R10; —Z—NR9—CO—R5; or —Z—CO2H and R3is a lone pair, or C1-C6-alkyl in which case the nitrogen atom to which it is attached is a quaternary nitrogen and carries a positive charge; R4is a group of formula (a), (b), (c) or (d); is an C1-C6-alkyl, aryl, aryl-fused-cycloalkyl, aryl-fused-heterocycloalkyl, heteroaryl, aryl(C1-C8-alkyl)-, heteroaryl(C1-C8-alkyl)-, cycloalkyl or heterocycloalkyl group, and the remaining variables are as defined in the specification.

REFERENCES:
patent: 4353922 (1982-10-01), Pfister
patent: 5610163 (1997-03-01), Banholzer et al.
patent: 2005/0025718 (2005-02-01), Meade et al.
patent: 2005/0209272 (2005-09-01), Forner et al.
patent: 0418716 (1991-03-01), None
patent: WO-02/060532 (2002-08-01), None
patent: WO-02/060533 (2002-08-01), None
patent: WO-03/087097 (2003-10-01), None
patent: WO-2004/074246 (2004-09-01), None
patent: WO-2004/089892 (2004-10-01), None
patent: WO-2004/105759 (2004-12-01), None
patent: WO-2005/111004 (2005-11-01), None
patent: WO-2006/017768 (2006-02-01), None
patent: WO-2006/023457 (2006-03-01), None
patent: WO-2006/023460 (2006-03-01), None
patent: WO-2006/035282 (2006-04-01), None
patent: WO-2006/035303 (2006-04-01), None
patent: WO 2006//048225 (2006-05-01), None
patent: WO-2010/071581 (2010-06-01), None
patent: WO-2010/071582 (2010-06-01), None
Carroll et al., “Synthesis and Muscarinic Receptor Activity of Ester Derivatives of 2-Substituted 2-Azabicyclo[2.2.1]heptan-5-ol and -6-ol”,J. Med. Chem. 35:2184-2191 (1992).
Pfister et al., “Synthesis and Bronchodilator Activity ofendo-2-(2-Cyclo-penty1-2-hydroxy-2-phenyl)acetoxy-7-methyl-7-azabicyclo-[2.2.1]heptane Methobromide, a Potent and Long-Acting Anticholinergic Agent”,J. Pharm. Sci. 74(2):208-210 (1985).
Gross et al., “Anticholinergic, Antimuscarinic Bronchodilators”,Am. Rev. Respir. Dis., vol. 129, pp. 856-870 (1984).
Gross et al., “Cholinergic Bronchomotor Tone in COPD*: Estimates of its Amount in Comparison with That in Normal Subjects”,Chest, vol. 96, No. 5, pp. 984-987 (1989).
Caulfield, Muscarinic Receptors-Characterization, Coupling and Function,Pharmac. Ther., vol. 58, pp. 319-379 (1993).
Fryer et al., “Muscarinic Receptors and Control of Airway Smooth Muscle”,Am. J. Respir. Crit. Care Med., vol. 158, pp. S154-S160 (1998).
Fryer et al., “Effects of Inflammatory Cells on Neuronal M2Muscarinic Receptor Function in the Lung”,Life Sciences, vol. 64, Nos. 6/7, pp. 449-455 (1999).
Pauwels et al., “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstruction Pulmonary Disease”,Am. J. Respir. Crit. Care Med., vol. 163, pp. 1256-1276 (2001).
Lee et al., “Selective Muscarinic Receptor Antagonists for Airway Diseases”,Current Opinion in Pharmacology, vol. 1, pp. 223-229 (2001).
Cazzola et al., “Ultra Long Acting β-Agonists in Development for Asthma and Chronic Obstructive Pulmonary Disease”,Expert Opin. Investig. Drugs, vol. 14, No. 7, pp. 775-783 (2005).

Affiliated with

Also associated with

Rating

Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2622119